Protocol Ledger

NCT06516679 · Phase II · RECRUITING

Efficacy of Risk-Stratified Treatment in Newly Diagnosed Infant Leukemia

Interventional Phase II clinical trial protocol NCT06516679 sponsored by Yonsei University in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2024-12-11 Enrollment: 40 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT06516679
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)40 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT06516679
Protocol FieldVerified Registry Value
NCT IdentifierNCT06516679
Consolidated Lead SponsorYonsei University
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II
Overall Recruitment StatusRECRUITING
Registered Enrollment40 participants (ESTIMATED)
Registered Start Date2024-12-11
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT06516679
Hospital Research SiteLocationSite Profile
Kyungpook National University Chilgok HospitalDaegu, South KoreaOpen Hospital Dossier ->
Chungnam National University HospitalDaejeon, South KoreaOpen Hospital Dossier ->
Chonnam National University Hwasun HospitalHwasun, South KoreaOpen Hospital Dossier ->
Asan Medical CenterSeoul, South KoreaOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI